| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
UAA crosslinker 1 does not have a specific biological target as a therapeutic agent. It is a click chemistry reagent containing an azide group for bioconjugation applications. The compound is used for the incorporation of non-canonical amino acids (ncAAs) into proteins via amber codon suppression. The azide group allows the modified amino acid to be selectively conjugated to alkyne-functionalized molecules through CuAAC or SPAAC reactions. This enables site-specific labeling, modification, and functionalization of proteins.
|
|---|---|
| ln Vitro |
UAA crosslinker 1 is a click chemistry reagent containing an azide (N3) moiety. It is used for the incorporation of non-canonical amino acids (ncAAs) via amber codon suppression. The azide group enables copper-catalyzed azide-alkyne cycloaddition (CuAAC) with alkyne-containing molecules and strain-promoted azide-alkyne cycloaddition (SPAAC) with DBCO- or BCN-containing molecules. The compound is also known as N6-((2-azidoethoxy)carbonyl)-L-lysine. It has a molecular weight of 259.26 and formula C9H17N5O4. It is used in protein engineering, bioconjugation, and chemical biology research.
|
| ln Vivo |
No in vivo activity data are documented for UAA crosslinker 1 as a therapeutic agent. The compound is a chemical biology tool used for protein labeling and modification in research settings. Its primary application is in vitro for the site-specific incorporation of non-canonical amino acids into proteins and subsequent bioconjugation. The compound may be used in cell culture for ncAA incorporation, but in vivo applications are limited.
|
| Enzyme Assay |
In vitro assays for UAA crosslinker 1 are not biological activity assays but rather chemical conjugation efficiency assays. The compound is evaluated for its ability to undergo CuAAC or SPAAC reactions with alkyne- or DBCO-functionalized molecules. Reaction efficiency is assessed by HPLC, mass spectrometry, or SDS-PAGE. The compound can be incorporated into proteins via amber codon suppression using cell-free or cell-based expression systems. Incorporation efficiency is confirmed by mass spectrometry or western blot after conjugation to a fluorescent or affinity tag.
|
| Cell Assay |
Cell-based assays for UAA crosslinker 1 involve the incorporation of non-canonical amino acids into proteins. Cells (typically E. coli or mammalian cells) are engineered with an orthogonal tRNA/aminoacyl-tRNA synthetase pair that recognizes the amber stop codon and incorporates the ncAA into the target protein. UAA crosslinker 1 is added to the cell culture medium, and the target protein is expressed. Protein expression is confirmed by SDS-PAGE and western blot. The incorporated azide group can be detected by conjugation to alkyne-functionalized fluorescent dyes via CuAAC, followed by in-gel fluorescence or flow cytometry.
|
| Animal Protocol |
Animal studies are not typically conducted with UAA crosslinker 1 as it is a chemical biology tool rather than a therapeutic agent. The compound is used for in vitro protein labeling and modification. For certain research applications, ncAA incorporation may be performed in cell culture or in vivo using transgenic animal models expressing the orthogonal tRNA/synthetase system. However, such applications are specialized and not widely reported. The compound is primarily used in biochemical and chemical biology research.
|
| ADME/Pharmacokinetics |
UAA crosslinker 1 has a molecular weight of 259.26 and molecular formula C9H17N5O4. It has a purity of ≥95%. The compound appears as a solid. It is soluble in organic solvents such as DMSO. The compound contains an azide group, which is potentially explosive and should be handled with care. It should be stored long-term in a cool, dry place. The compound is stable under normal storage conditions. Solutions should be prepared fresh before use and protected from light.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for UAA crosslinker 1. The compound contains an azide group, which can be potentially hazardous and should be handled with appropriate safety precautions. Azides may be toxic and can form explosive compounds with certain metals. Standard laboratory safety practices including the use of personal protective equipment (gloves, lab coat, safety goggles) and proper ventilation should be followed. The compound is intended for research use only and is not approved for human therapeutic applications.
|
| Additional Infomation |
(2S)-2-amino-6-{[(2-azidoethoxy)carbonyl]amino}hexanoic acid is an organic molecular entity.
UAA crosslinker 1 is also known as (2S)-2-amino-6-{[(2-azidoethoxy)carbonyl]amino}hexanoic acid, N6-((2-azidoethoxy)carbonyl)-L-lysine, or NEpsilon-2-Azidoethyloxycarbonyl-L-lysine. It is a click chemistry reagent containing an azide group for CuAAC and SPAAC reactions. The compound is used for the incorporation of non-canonical amino acids (ncAAs) via amber codon suppression. It is used in protein engineering, bioconjugation, and chemical biology research. The compound is intended for research use only and is not for human therapeutic use. |
| Molecular Formula |
C9H17N5O4
|
|---|---|
| Molecular Weight |
259.262
|
| Exact Mass |
259.128
|
| CAS # |
1167421-25-1
|
| Related CAS # |
UAA crosslinker 1 hydrochloride;1994331-17-7
|
| PubChem CID |
49842364
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.149
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
18
|
| Complexity |
316
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N[C@@H](CCCCNC(OCCN=[N+]=[N-])=O)C(O)=O
|
| InChi Key |
RPLCQQYRZLXMKL-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C9H17N5O4/c10-7(8(15)16)3-1-2-4-12-9(17)18-6-5-13-14-11/h7H,1-6,10H2,(H,12,17)(H,15,16)/t7-/m0/s1
|
| Chemical Name |
(2S)-2-amino-6-(2-azidoethoxycarbonylamino)hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8571 mL | 19.2857 mL | 38.5713 mL | |
| 5 mM | 0.7714 mL | 3.8571 mL | 7.7143 mL | |
| 10 mM | 0.3857 mL | 1.9286 mL | 3.8571 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
